Synthesis and Src kinase inhibitory activity of 2-phenyl- and 2-thienyl-7-phenylaminothieno[3,2-b]pyridine-6-carbonitriles

被引:48
作者
Boschelli, DH [1 ]
Wu, B [1 ]
Sosa, ACB [1 ]
Durutlic, H [1 ]
Chen, JJ [1 ]
Wang, Y [1 ]
Golas, JM [1 ]
Lucas, J [1 ]
Boschelli, F [1 ]
机构
[1] Wyeth Ayerst Res, Chem & Screening Sci & Oncol, Pearl River, NY 10965 USA
关键词
D O I
10.1021/jm050175p
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
2-Phenyl-7-phenylaminothieno[3,2-b]pyridine-6-carbonitriles were recently reported to be inhibitors of Src kinase activity. In this study we present structure-activity relationships for additional thieno[3,2-b]pyridine-6-carbonitriles, modifying the substituents on the C-2 phenyl and C-7 phenylamino groups. Derivatives with various aminomethyl and aminoethyl substituents on the para position of the C-2 phenyl group retained the activity of the initial analogues. However, direct attachment of an amino group led to decreased activity. A 2,4-dichloro-5-methoxyphenylamino group at C-7 provided superior inhibition of Src enzymatic activity. Replacement of the C-2 phenyl group with a 3,5-substituted thiophene led to improved Src inhibitory activity compared to the parent compound, but other thiophene isomers were less active. One of the analogues reported here exhibited in vivo activity comparable to that of SKI-606, a related 3-quinolinecarbonitrile currently in clinical trials.
引用
收藏
页码:3891 / 3902
页数:12
相关论文
共 35 条
[21]  
Myoui A, 2003, CANCER RES, V63, P5028
[22]   Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML [J].
O'Hare, T ;
Pollock, R ;
Stoffregen, EP ;
Keats, JA ;
Abdullah, OM ;
Moseson, EM ;
Rivera, VM ;
Tang, H ;
Metcalf, CA ;
Bohacek, RS ;
Wang, YH ;
Sundaramoorthi, R ;
Shakespeare, WC ;
Dalgarno, D ;
Clackson, T ;
Sawyer, TK ;
Deininger, MW ;
Druker, BJ .
BLOOD, 2004, 104 (08) :2532-2539
[23]   Src family kinases, key regulators of signal transduction [J].
Parsons, SJ ;
Parsons, JT .
ONCOGENE, 2004, 23 (48) :7906-7909
[24]   Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke [J].
Paul, R ;
Zhang, ZG ;
Eliceiri, BP ;
Jiang, Q ;
Boccia, AD ;
Zhang, RL ;
Chopp, M ;
Cheresh, DA .
NATURE MEDICINE, 2001, 7 (02) :222-227
[25]   Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth [J].
Roginskaya, V ;
Zuo, S ;
Caudell, E ;
Nambudiri, C ;
Kraker, AJ ;
Corey, SJ .
LEUKEMIA, 1999, 13 (06) :855-861
[26]   Resistance to imatinib: more and more mutations [J].
Sawyers, CL .
BLOOD, 2003, 102 (01) :4-5
[27]   Overriding imatinib resistance with a novel ABL kinase inhibitor [J].
Shah, NP ;
Tran, C ;
Lee, FY ;
Chen, P ;
Norris, D ;
Sawyers, CL .
SCIENCE, 2004, 305 (5682) :399-401
[28]   Src inhibitors: drugs for the treatment of osteoporosis, cancer or both? [J].
Susa, M ;
Missbach, M ;
Green, J .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2000, 21 (12) :489-495
[29]   INCREASE IN ACTIVITY AND LEVEL OF PP60C-SRC IN PROGRESSIVE STAGES OF HUMAN COLORECTAL-CANCER [J].
TALAMONTI, MS ;
ROH, MS ;
CURLEY, SA ;
GALLICK, GE .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (01) :53-60
[30]   Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate [J].
Tipping, AJ ;
Baluch, S ;
Barnes, DJ ;
Veach, DR ;
Clarkson, BM ;
Bornmann, WG ;
Mahon, FX ;
Goldman, JM ;
Melo, JV .
LEUKEMIA, 2004, 18 (08) :1352-1356